5HZ1 Stock Chart & Stats
€5.70
-€0.08(-2.33%)
At close: 4:00 PM EST
€5.70
-€0.08(-2.33%)
Day’s Range― - ―
52-Week Range€3.22 - €5.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.67B
Enterprise Value€33.48K
Total Cash (Recent Filing)€2.15B
Total Debt (Recent Filing)€2.35B
Price to Earnings (P/E)710.0
Beta0.75
Next Earnings
Oct 22, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding123,124,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)4.81
P/FCF Ratio36.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.88Price Target Upside3.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.08
Revenue Forecast (FY)€1.01B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and substantial equity provide financial resilience through business cycles. This gives Tigermed flexibility to fund operations, absorb volatility, and pursue development opportunities without relying heavily on borrowing or exposing cash flow to excessive financing costs.
Strong Free Cash FlowSustained positive operating and free cash flow indicates that the CRO model is generating cash to support reinvestment and financial obligations. Strong recent free-cash-flow growth and healthy conversion from earnings improve internal funding capacity over the next several quarters.
Revenue Growth ResumedThe return to revenue growth after a 2024 decline suggests renewed demand for Tigermed's outsourced clinical research and development-support services. If sustained, improving activity levels can strengthen utilization, expand customer engagement, and rebuild operating leverage.
Bears Say
Material Margin CompressionThe sharp decline in gross and net margins shows that revenue growth has not translated into the profitability previously achieved. Persistent margin pressure would reduce earnings scalability, weaken returns on the company's substantial equity base, and constrain reinvestment capacity.
Sharp Earnings DeteriorationThe steep reduction in net income indicates materially weaker earnings power than in prior periods, while low ROE shows inefficient use of the equity base. Unless profitability recovers, weaker returns could limit capital generation and reduce the durability of the growth profile.
Cash-flow Coverage VolatilityAlthough free cash flow remains positive, uneven operating-cash-flow coverage means reported profitability does not consistently convert into operating cash at a high rate. Working-capital or timing volatility can make funding needs less predictable and complicate planning during expansion.
Hangzhou Tigermed Consulting Co., Ltd. Class H News
5HZ1 FAQ
What was Hangzhou Tigermed Consulting Co., Ltd. Class H’s price range in the past 12 months?
Hangzhou Tigermed Consulting Co., Ltd. Class H lowest stock price was €3.22 and its highest was €5.90 in the past 12 months.
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap is €5.67B.
When is Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date is Oct 22, 2026 which is in 22 days.
How were Hangzhou Tigermed Consulting Co., Ltd. Class H’s earnings last quarter?
Hangzhou Tigermed Consulting Co., Ltd. Class H released its earnings results on Aug 28, 2026. The company reported -€0.07 earnings per share for the quarter, missing the consensus estimate of €0.028 by -€0.098.
Is Hangzhou Tigermed Consulting Co., Ltd. Class H overvalued?
According to Wall Street analysts Hangzhou Tigermed Consulting Co., Ltd. Class H’s price is currently Undervalued.
Does Hangzhou Tigermed Consulting Co., Ltd. Class H pay dividends?
Hangzhou Tigermed Consulting Co., Ltd. Class H does not currently pay dividends.
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate is 0.04.
How many shares outstanding does Hangzhou Tigermed Consulting Co., Ltd. Class H have?
Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding.
What happened to Hangzhou Tigermed Consulting Co., Ltd. Class H’s price movement after its last earnings report?
Hangzhou Tigermed Consulting Co., Ltd. Class H reported an EPS of -€0.07 in its last earnings report, missing expectations of €0.028. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Hangzhou Tigermed Consulting Co., Ltd. Class H?
Currently, no hedge funds are holding shares in DE:5HZ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hangzhou Tigermed Consulting Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
0.31%
Trailing 12-Months
Asset Growth
6.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
5HZ1 Stock 12 Month Forecast
Average Price Target
€5.88
▲(3.10% Upside)
Technical Analysis
WuXi AppTec Co., Ltd. Class H
―
JOINN Laboratories (China) Co., Ltd. Class H
―
Mega Genomics Limited
―
ADICON Holdings Limited
―
WuXi XDC Cayman, Inc.
―